Literature DB >> 19844628

Intraventricular hemorrhage long after successful encephaloduroarterio synangiosis in moyamoya patient.

Moon Young Chung1, Young Seok Park, Dong-Seok Kim, Joong-Uhn Choi.   

Abstract

Intraventricular hemorrhage long after successful encephaloduroarterio synangiosis (EDAS) is very rare. The effect of revascularization surgery for preventing hemorrhagic event of moyamoya disease remains controversial. We report a 17-year-old female with intracerebral hemorrhage and intraventricular hemorrahge 10 years after successful EDAS. Even though cerebral vessels angiography showed good collateral circulations without specific weak points, a cerebral hemorrhage could occur in patient with ischemic type of moyamoya disease long after successful indirect bypass operations. Good collateralization of cerebral angiography or magnetic resonance perfusion image after indirect bypass surgery would ensure against ischemic symptoms, not a hemorrhage. And, thus a life-time follow-up strategy might be necessary even if a good collateral circulation has been established.

Entities:  

Keywords:  Intracranial hemorrhage; Ischemic attack; Moyamoya disease; Perfusion

Year:  2009        PMID: 19844628      PMCID: PMC2764026          DOI: 10.3340/jkns.2009.46.3.257

Source DB:  PubMed          Journal:  J Korean Neurosurg Soc        ISSN: 1225-8245


  16 in total

Review 1.  Moyamoya disease: current concepts and future perspectives.

Authors:  Satoshi Kuroda; Kiyohiro Houkin
Journal:  Lancet Neurol       Date:  2008-11       Impact factor: 44.182

2.  Long-term outcomes of pediatric moyamoya disease treated by encephalo-duro-arterio-synangiosis.

Authors:  Mitsuo Isono; Keisuke Ishii; Tohru Kamida; Ryo Inoue; Minoru Fujiki; Hidenori Kobayashi
Journal:  Pediatr Neurosurg       Date:  2002-01       Impact factor: 1.162

3.  Clinical course, surgical management, and long-term outcome of moyamoya patients with rebleeding after an episode of intracerebral hemorrhage: An extensive follow-Up study.

Authors:  Y Yoshida; T Yoshimoto; R Shirane; Y Sakurai
Journal:  Stroke       Date:  1999-11       Impact factor: 7.914

4.  Asymptomatic microbleeds in moyamoya disease: T2*-weighted gradient-echo magnetic resonance imaging study.

Authors:  Ken-Ichiro Kikuta; Yasushi Takagi; Kazuhiko Nozaki; Takashi Hanakawa; Tsutomu Okada; Nobuhro Mikuni; Yukio Miki; Yasutaka Fushmi; Akira Yamamoto; Keisuke Yamada; Hidenao Fukuyama; Nobuo Hashimoto
Journal:  J Neurosurg       Date:  2005-03       Impact factor: 5.115

5.  Long-term natural history of hemorrhagic moyamoya disease in 42 patients.

Authors:  E Kobayashi; N Saeki; H Oishi; S Hirai; A Yamaura
Journal:  J Neurosurg       Date:  2000-12       Impact factor: 5.115

6.  Effectiveness of superficial temporal artery-middle cerebral artery anastomosis in adult moyamoya disease: cerebral hemodynamics and clinical course in ischemic and hemorrhagic varieties.

Authors:  Y Okada; T Shima; M Nishida; K Yamane; T Yamada; C Yamanaka
Journal:  Stroke       Date:  1998-03       Impact factor: 7.914

Review 7.  Revascularisation surgery for paediatric moyamoya: a review of the literature.

Authors:  Lai-Wah Eva Fung; Dominic Thompson; Vijeya Ganesan
Journal:  Childs Nerv Syst       Date:  2005-02-05       Impact factor: 1.475

8.  Clinical features of the haemorrhage type moyamoya disease based on 31 cases.

Authors:  S Kawaguchi; T Sakaki; T Kakizaki; K Kamada; T Shimomura; H Iwanaga
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

9.  High-risk age for rebleeding in patients with hemorrhagic moyamoya disease: long-term follow-up study.

Authors:  Motohiro Morioka; Jun-Ichiro Hamada; Tatemi Todaka; Shigetoshi Yano; Yutaka Kai; Yukitaka Ushio
Journal:  Neurosurgery       Date:  2003-05       Impact factor: 4.654

10.  Study design for a prospective randomized trial of extracranial-intracranial bypass surgery for adults with moyamoya disease and hemorrhagic onset--the Japan Adult Moyamoya Trial Group.

Authors:  Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2004-04       Impact factor: 1.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.